Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study

Table 5 Univariate and multivariate analysis of ePFS

Independent risk factor		Univariate analysis of ePFS			Multivariate analysis of ePFS
Independent risk factor		P value	HR value	95% CI	P value	HR value	95% CI
First line regimens	Group C + D: Group A + B	0.009	0.507	0.304–0.846	0.010	0.508	0.305–0.848
	Group B: Group A	0.038	0.658	0.442–0.978
Age	< 70: ≥ 70	0.345	0.810	0.522–1.255
Gender	Female: male	0.484	0.881	0.618–1.256
Intracranial symptoms	No: Yes	0.275	1.233	0.846–1.795
Smoking	No: Yes	0.159	0.741	0.489–1.124
*EGFR* mutation	Sensitive mutation: others	0.049	0.529	0.245–1.143	0.110	0.534	0.247–1.153
	19DEL: 21L858R	0.188	1.272	0.889–1.821

Note: Group A: 1st generation EGFR-TKIs monotherapy; Group B: 1st generation EGFR-TKIs + pemetrexed plus cisplatin/carboplatin chemotherapy; Group C: 1st generation EGFR-TKIs + bevacizumab; Group D: 1st generation EGFR-TKIs + pemetrexed plus cisplatin/carboplatin chemotherapy + bevacizumab
Abbreviations: ePFS, extracranial progression-free survival; TKI, tyrosine kinase inhibitor

ISSN: 1471-2407